Posted on August 10th, 2014
Mr. Commissiong was appointed President and CEO of Amarantus BioScience in October 2011.
Amarantus BioScience Holdings, Inc. is a biotechnology company developing treatments and diagnostics for diseases associated with neurodegeneration and protein misfolding-related apoptosis. The Company has licensed Eltoprazine (“Eltoprazine”), a phase 2b ready indication for Parkinson’s Levodopa induced dyskinesia and Adult ADHD. The Company has an exclusive worldwide license to the Lymphocyte Proliferation test (“LymPro Test®”) for Alzheimer’s disease and owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor (“MANF”) and is developing MANF-based products as treatments for brain disorders. Amarantus is a Founding Member of the Coalition for Concussion Treatment (#C4CT), a movement initiated in collaboration with Brewer Sports International seeking to raise awareness of new treatments in development for concussions and nervous-system disorders. The Company also owns intellectual property for the diagnosis of Parkinson’s disease (“NuroPro”) and the discovery of neurotrophic factors (“PhenoGuard”).
On Friday, August 8th, 2014, we filed a preliminary proxy statement with the United States Securities and Exchange Commi...Read More »
Posted on August 6th, 2014
Dear Readers, Welcome to the inaugural Matinas BioPharma CEO Blog! I am very excited to share some of our learning’...Read More »
Posted on August 4th, 2014
The month of July turned out to be an incredible fundamental value-building month for Amarantus. We completed our 3rd #C...Read More »
Reveal Insights About Your Company and Industry to Shareholders.
We are an exclusive, online media publication where public and privatively held firms alike share insights about their companies and industries...Learn More »